의생명과학과

At the Chong Kun Dang New Drug Research Institute, I have been involved in the development of new antifungals (A Study for the Development of New Antifungals), development of solid cancer treatments derived from natural products, research on enzymatic optical cleavage of antiviral nucleosides, and antiviral drugs (5-methoxymethyluridine). A Study for the Development of Antivirals, Development of Fumagillin Derivatives, An Antiangiogenic Antitumor Agent, Clinical Development of Camptothecin Anticancer Agents A Camptothecin Derivatives Antitumor Agent), HCV polymerase inhibitor research, Cathepsin-K inhibitor research, HBV Antiviral nucleoside analogues research, -HIV-RT inhibitor research, and Melanocortin-4 inhibitor research were conducted. In 2000, the company was established and Pan-Raf Inhibitor was established. , RIPK1 Inhibitor (AD, ALS, MS, PD), Autoimmune Diseases, Fibrosis, NASH, Immuno-Oncology, CNS & Autoimmune Diseases, fibrostenotic Crohn's disease research, Parkinson's disease treatment joint development research, ADC development and manufacturing, retinal disease We conducted joint development research on treatments.
The major participating academic organizations are The Korean Chemical Society, The Korean Biochemical Society, The Korean Pharmaceutical Association, and The Korean Cancer Association.